Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC | Cancer Discovery | American Association for Cancer Research #JNJ #Amivantamab #EGFR #Ex20ins https://t.co/qN7L8eFl
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
RT @VivekSubbiah: In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in D…
In the context of FDA approval 👉🏼Anti-tumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC in @CD_AACR https://t.co/PrtXLcxAFk
RT @ElizSMcKenna: Amivantamab has been approved for #EGFR exon20-mutant NSCLC! Read the first report of its activity in these tumors in @CD…
RT @CD_AACR: Related: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20…
RT @CD_AACR: Related: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20…
RT @CD_AACR: Related: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20…
Related: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC. https://t.co/Dw5cVCgr3A
RT @ElizSMcKenna: Amivantamab has been approved for #EGFR exon20-mutant NSCLC! Read the first report of its activity in these tumors in @CD…
Amivantamab has been approved for #EGFR exon20-mutant NSCLC! Read the first report of its activity in these tumors in @CD_AACR: https://t.co/mmmox5yYrI
RT @ElizSMcKenna: ICYMI in @CD_AACR: Preclinical and initial clinical antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispec…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
Antitumor Activity of #Amivantamab (JNJ-61186372), an #EGFR_MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven #NSCLC: https://t.co/CcbsSYFB2O
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #LungCancerAwarenessMonth https://t.co/VK0rx2dS9E https://t.co/H4IOzU8qw7
@OncoAlert @lcsmchat @isliquidbiopsy @OncoReporte
RT @CD_AACR: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–s…
RT @CD_AACR: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–s…
RT @CD_AACR: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–s…
RT @CD_AACR: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–s…
RT @CD_AACR: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–s…
RT @CD_AACR: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–s…
RT @CD_AACR: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–s…
Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC #ENASymp https://t.co/dKnfVZYTOr https://t.co/fRiL4YW1Z4
RT @mathew_carter1: For those interested in developments in pts with EGFR Ex20 insertions @team_lung @ECMC_Manchester @MFT_Genomics Antit…
RT @ElizSMcKenna: Watching the presentation on amivantamab plus lazertinib in NSCLC at #ESMO20 - ICYMI in @CD_AACR: Antitumor activity of a…
RT @ElizSMcKenna: Watching the presentation on amivantamab plus lazertinib in NSCLC at #ESMO20 - ICYMI in @CD_AACR: Antitumor activity of a…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC #ESMO20 https://t.co/j7dz8TQ7cC https://t.co/Zm1cPPAKEv
Watching the presentation on amivantamab plus lazertinib in NSCLC at #ESMO20 - ICYMI in @CD_AACR: Antitumor activity of amivantamab in diverse models of EGFR exon 20 insertion–driven NSCLC https://t.co/mmmox5yYrI
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @mathew_carter1: For those interested in developments in pts with EGFR Ex20 insertions @team_lung @ECMC_Manchester @MFT_Genomics Antit…
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @mathew_carter1: For those interested in developments in pts with EGFR Ex20 insertions @team_lung @ECMC_Manchester @MFT_Genomics Antit…
For those interested in developments in pts with EGFR Ex20 insertions @team_lung @ECMC_Manchester @MFT_Genomics Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC ht
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
RT @AndresFCardonaZ: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 I…
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC - For exon 20ins lovers https://t.co/8JN1RRy2m6
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC #cancer #lung #next https://t.co/TZecX4VNXG
RT @JianjiaoN: We recently treated a heavily metastatic patient with EGFR exon 20 insertion who failed first-line chemotherapy with PD-1mab…
RT @JianjiaoN: We recently treated a heavily metastatic patient with EGFR exon 20 insertion who failed first-line chemotherapy with PD-1mab…
We recently treated a heavily metastatic patient with EGFR exon 20 insertion who failed first-line chemotherapy with PD-1mab+GM-CSF+SBRT (to a single metastatic lesion) in our phase II trial. PR (target lesion shrink more than 80%)
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
Step by step 💊🌡🔬
Targeting rare EGFR mutations in NSCLC https://t.co/UUo0XHJ6jM